- “ABRAXANE Approved for Advanced Breast Cancer Patient Treatment in Quebec” (Press release issued by Abraxis BioScience, Business Wire)
- “Forum Exchanges Ideas Impacting Drug Approvals” (San Diego Business Journal)
- “Israel sets up 1 billion shekel biotech fund” (Reuters)
- “Q+A-Sanofi’s Lantus linked to cancer: what is known?” (Reuters, Forbes)
- “Teva, Antares get FDA nod for needle-free device” (Reuters)
- “FDA weighs options to reduce painkiller overdoses” (The Washington Post)
- “Paladin to buy some products from Wyeth” (Reuters)
- “Biocon forms alliance with Mylan” (Business Standard)
- “New Cancer Treatment Shows Promise in Testing” (The New York Times)
- “Biotech Start-Ups Show Dedication, Line Up Again for Tax Credits” (The Washington Post)
- “Biotech: Generics Win a Round” (BusinessWeek)
- “Takeda shares hurt by diabetes drug U.S. setback” (Reuters)
- “Australian scientists kill cancer cells with “trojan horse” (Reuters)
- “Celera in licensing agreement with Bayer Schering” (The Associated Press, Forbes)
- “Glaxo plans 6-yr euro benchmark bond –IFR” (Reuters)
- “Novartis in Talks For Parts of Elan” (TheStreet.com)
- “Gilead gets positive nod on cystic fibrosis drug” (The Associated Press)
THE LATEST WORD
Top Industry Stories – June 29, 2009
Posted on June 29th, 2009 | by Rxmedyn | No Comments »Posted in Industry Stories
SUBSCRIBE-
Recent Posts
Archives
Careers | © 2009 Medical Dynamics